X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs CADILA HEALTHCARE - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES CADILA HEALTHCARE PIRAMAL ENTERPRISES/
CADILA HEALTHCARE
 
P/E (TTM) x 9.1 24.0 37.9% View Chart
P/BV x 3.0 6.0 50.0% View Chart
Dividend Yield % 0.8 0.8 103.5%  

Financials

 PIRAMAL ENTERPRISES   CADILA HEALTHCARE
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
CADILA HEALTHCARE
Mar-17
PIRAMAL ENTERPRISES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs2,095460 455.4%   
Low Rs1,025305 336.1%   
Sales per share (Unadj.) Rs492.892.1 535.0%  
Earnings per share (Unadj.) Rs72.614.8 489.7%  
Cash flow per share (Unadj.) Rs94.718.5 512.3%  
Dividends per share (Unadj.) Rs21.003.20 656.3%  
Dividend yield (eoy) %1.30.8 160.9%  
Book value per share (Unadj.) Rs862.568.0 1,268.6%  
Shares outstanding (eoy) m172.561,023.74 16.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.24.2 76.2%   
Avg P/E ratio x21.525.8 83.3%  
P/CF ratio (eoy) x16.520.7 79.6%  
Price / Book Value ratio x1.85.6 32.1%  
Dividend payout %28.921.6 134.0%   
Avg Mkt Cap Rs m269,194391,581 68.7%   
No. of employees `0004.016.9 23.8%   
Total wages/salary Rs m17,93915,002 119.6%   
Avg. sales/employee Rs Th21,190.35,594.5 378.8%   
Avg. wages/employee Rs Th4,470.1890.1 502.2%   
Avg. net profit/employee Rs Th3,120.0899.9 346.7%   
INCOME DATA
Net Sales Rs m85,03794,295 90.2%  
Other income Rs m2,3381,286 181.8%   
Total revenues Rs m87,37495,581 91.4%   
Gross profit Rs m34,99119,036 183.8%  
Depreciation Rs m3,8173,750 101.8%   
Interest Rs m20,310450 4,513.3%   
Profit before tax Rs m13,20216,122 81.9%   
Minority Interest Rs m1,699338 502.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-100-3 3,316.7%   
Tax Rs m2,2811,289 177.0%   
Profit after tax Rs m12,52015,168 82.5%  
Gross profit margin %41.120.2 203.8%  
Effective tax rate %17.38.0 216.1%   
Net profit margin %14.716.1 91.5%  
BALANCE SHEET DATA
Current assets Rs m87,59060,223 145.4%   
Current liabilities Rs m185,57853,058 349.8%   
Net working cap to sales %-115.27.6 -1,516.5%  
Current ratio x0.51.1 41.6%  
Inventory Days Days3170 44.5%  
Debtors Days Days4888 53.9%  
Net fixed assets Rs m108,52372,984 148.7%   
Share capital Rs m3451,024 33.7%   
"Free" reserves Rs m148,48168,576 216.5%   
Net worth Rs m148,82669,600 213.8%   
Long term debt Rs m144,95724,684 587.3%   
Total assets Rs m482,394152,207 316.9%  
Interest coverage x1.736.8 4.5%   
Debt to equity ratio x1.00.4 274.6%  
Sales to assets ratio x0.20.6 28.5%   
Return on assets %6.810.3 66.3%  
Return on equity %8.421.8 38.6%  
Return on capital %12.017.9 66.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,00121,280 70.5%   
Fx outflow Rs m5,15010,874 47.4%   
Net fx Rs m9,85110,406 94.7%   
CASH FLOW
From Operations Rs m-100,39313,495 -743.9%  
From Investments Rs m-24,202-29,103 83.2%  
From Financial Activity Rs m135,70523,158 586.0%  
Net Cashflow Rs m11,1107,556 147.0%  

Share Holding

Indian Promoters % 52.9 74.8 70.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 8.3 48.2%  
FIIs % 26.6 5.9 450.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 11.0 150.0%  
Shareholders   93,274 44,069 211.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  PLETHICO PHARMA  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jun 22, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS